Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 7/20 | 0.41 |
| ▸ | RAB9A | P51151 | 6/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | DDX3X | O00571 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5984327 | 0.88 | DGAT1 (0.59) | CYP1A2DGAT1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1748153 | 0.88 | DGAT1 (0.59) | CYP1A2DGAT1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1748064 | 0.78 | DGAT1 (0.48) | CYP1A2DGAT1NPC1RAB9ASMN1; SMN2 | |
| Bicarbonate SCHEMBL2310230 | 0.76 | NPC1 (0.52) | CYP1A2DGAT1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2306515 | 0.75 | DGAT1 (0.55) | CYP1A2DGAT1LMNA | |
| SCHEMBL2307115 | 0.75 | DGAT1 (0.61) | CYP1A2DGAT1MEN1KMT2A | |
| SCHEMBL2310394 | 0.75 | CYP1A2 (0.58) | CYP1A2DGAT1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2309237 | 0.75 | CYP1A2 (0.58) | CYP1A2DGAT1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2310397 | 0.75 | CYP1A2 (0.58) | CYP1A2DGAT1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6833103 | 0.74 | DGAT1 (0.64) | DGAT1NPC1RAB9ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091228-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-08-15 | — | — | US | disclosed |
| US-20040224997-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224997-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | FABP4, GPR119, LIPC | CYP1A2 98/4885DGAT1 34/4885NPC1 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.